股份代號 : 2325 （於開曼群島註冊成立的有限公司） 2023 中期報告 深度服務 . 精益運營 目錄 釋義及技術詞彙 2 公司資料 5 財務摘要 7 管理層討論及分析 10 企業管治及其他資料 29 中期簡明綜合全面收益表 36 中期簡明綜合財務狀況表 38 中期簡明綜合權益變動表 40 中期簡明綜合現金流量表 41 中期簡明綜合財務報表附註 42 釋義及技術詞彙 | --- | --- | --- | |---------------------------------|-------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------| | | | ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示概不就因本公告全部或任何部分內容所產生或因依賴 該等內容而引致的任何損失承擔任何責任。 截至6月30日止六個月 2023年 2022年 變動 人民幣千元 人民幣千元 （未經審核）（未經審核） 收益 476,865 1,378,656 (65.4)% －診斷外包服務 254,438 680,362 (62.6)% －為醫聯體提供的診斷檢測服務 197,876 650,700 (69.6)% －為非醫療機構提供的診斷檢測服務 24,551 47,594 (48.4)% 收益成本 (295,200) (727,584) (59.4)% 毛利 181,665 651,072 (72.1)% 除所得稅前溢利 50,809 283,500 (82.1)% 期內溢利 48,027 234,761 (79.5)% 本公司擁有人應佔溢利： 48,715 234,363 (79.2)% 1 Yunkang Group Limited 雲康集團有限公司 （於開曼群島註冊成立的有限公司） （股份代號：2325） 截 ...

Financial Performance - The company reported a revenue of $500 million for the fiscal year, representing a 20% increase year-over-year[1]. - The company provided guidance for the next fiscal year, projecting a revenue increase of 25% to $625 million[3]. - The company reported revenue of RMB 3,756.2 million for the year ended December 31, 2022, representing a 121.4% increase compared to RMB 1,696.7 million in 2021[13]. - Revenue from diagnostic outsourcing services reached RMB 1,944.2 million, an increase of 89.8% from RMB 1,024.3 million in the previous year[16]. - Revenue from diagnostic testing services provided to medical alliances grew by 171.3%, reaching RMB 1,680.6 million compared to RMB 619.4 million in 2021[16]. - The gross profit for the year was RMB 1,307.7 million, reflecting a 45.4% increase from RMB 899.1 million in 2021[13]. - The company's net profit for the year was RMB 373.9 million, a decrease of 2.1% from RMB 381.9 million in the previous year[13]. - The company's revenue reached RMB 3,756.2 million, representing a year-on-year growth of 121.4%, with an overall gross margin of 34.8%[32]. - The group's profit recorded was RMB 373.9 million, a slight decrease of 2.1% compared to 2021, primarily due to a significant reduction in the average price of COVID-19 testing[17]. User Growth and Market Expansion - User data showed a growth of 15% in active users, reaching 2 million by the end of the reporting period[2]. - The company is expanding its market presence in Southeast Asia, targeting a 10% market share by the end of the next fiscal year[5]. - The number of on-site diagnostic centers increased from 275 as of December 31, 2021, to 398 as of December 31, 2022[16]. - As of December 31, 2022, the company established 398 on-site diagnostic centers nationwide, serving over 840 medical institutions within medical alliances[36]. Research and Development - Research and development expenses increased by 30%, totaling $75 million, to support innovation initiatives[6]. - R&D expenses increased by 115.6% from RMB 43.9 million in 2021 to RMB 94.7 million in 2022, reflecting increased investment in ongoing and new R&D projects[59]. - The company aims to enhance its diagnostic capabilities, particularly in oncology, genetic diseases, infectious diseases, and pathology[49]. Strategic Initiatives and Partnerships - New product launches included a cutting-edge diagnostic tool, expected to generate $50 million in revenue within the first year[4]. - A new strategic partnership was formed with a leading tech firm, aimed at integrating advanced technologies into existing products[8]. - The company completed an acquisition of a competitor for $100 million, enhancing its product portfolio and market reach[7]. - The company has formed a joint laboratory with Roche, focusing on precision medical fields to accelerate the application of innovative diagnostic technologies[37]. - Collaborations with Danaher Group's Beckman Coulter, Leica, and Cepheid aim to enhance laboratory research and clinical application integration, particularly in cancer, reproductive genetics, and infectious diseases[37]. Operational Efficiency - The company reported a net profit margin of 15%, up from 12% in the previous year, indicating improved operational efficiency[9]. - Cash flow from operations increased by 40%, reaching $120 million, providing a strong liquidity position for future investments[10]. - The average revenue per on-site diagnostic center increased from RMB 2.2 million in 2021 to RMB 4.2 million in 2022[16]. - The company emphasizes "lean operations" to optimize organizational models and operational processes, focusing on quality, cost, and efficiency[23]. - The establishment of a full-process lean management service system supports the company's customer-centric deep service system[23]. Corporate Governance - The company has maintained compliance with corporate governance codes since its listing date, with the exception of a deviation regarding the separation of the roles of Chairman and CEO[93]. - The board consists of one executive director, three non-executive directors, and three independent non-executive directors, ensuring a balanced governance structure[94]. - The company has established three committees: audit, remuneration, and nomination, to oversee various aspects of governance[102]. - The company is committed to high standards of corporate governance, which is believed to enhance shareholder value and accountability[93]. Employee and Diversity Initiatives - The group reported a total employee count of 2,605 as of December 31, 2022, an increase from 1,868 in 2021, reflecting a growth of approximately 39.3%[132]. - The company aims to enhance gender diversity at all levels, including the board and senior management, by implementing measures such as recruiting employees of different genders and providing career development opportunities[108]. - The company has a zero-tolerance policy towards discrimination based on gender, age, race, nationality, and disability, ensuring equal employment opportunities for all[110]. Risk Management - The board is responsible for the risk management and internal control systems, which are designed to identify and assess significant new risks dynamically and effectively[118]. - The company encourages employees to adopt proactive risk management approaches to enhance the group's risk awareness culture[119]. - The company faces risks related to fluctuating demand for COVID-19 testing services, which could impact revenue from this segment[129]. Future Outlook - The company anticipates significant growth opportunities in the third-party medical testing industry due to increased healthcare demand and government support[30]. - The company plans to enhance its digital operations by establishing a digital platform for end-to-end sample management in laboratory settings[26]. - The company aims to deepen its service system and improve operational efficiency while focusing on quality growth[49].

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示概不就因本公告全部或任何部分內容所產生或因依賴 該等內容而引致的任何損失承擔任何責任。 Yunkang Group Limited 雲康集團有限公司 （於開曼群島註冊成立的有限公司） （股份代號：2325） 截至2022年12月31日止年度的年度業績公告 云康集团有限公司（「本公司」，連同其附屬公司及綜合聯屬實體，定義見本公司 日期為2022年5月5日的招股章程（「招股章程」），統稱為「本集團」）董事（「董事」） 會（「董事會」）欣然宣佈本集團截至2022年12月31日止年度（「報告期」）的經審核 綜合業績，連同截至2021年12月31日止年度的比較數字。 於本公告中，「我們」及「我們的」指本公司及本集團（如文義另有所指）。本公告所 載若干金額及百分比數字已約整，或約整至一位或兩位小數。任何表格、圖表或 其他地方的總額與其中所列金額總和之間的任何差異乃因約整所致。 1 財務摘要 | --- | --- | --- | --- | |------------------------------ ...